title: Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.
abstract: ACE inhibition protects kidney function, but ACE insertion/deletion (I/D) polymorphism affects renal prognosis in type 1 diabetic patients. ACE genotype may influence the renal benefits of ACE inhibition. We studied the impact of ACE I/D polymorphism on the renal hemodynamic changes induced by ACE inhibition in type 1 diabetes. We studied renal hemodynamics (glomerular filtration rate [GFR], effective renal plasma flow [ERPF], filtration fraction [GFR/ERPF], mean arterial pressure [MAP], and total renal resistances [MAP/ERPF]) repeatedly during normoglycemia and then hyperglycemia in 12 normotensive, normoalbuminuric type 1 diabetes and the II genotype (associated with nephroprotection) versus 22 age- and sex-matched subjects with the ACE D allele after three randomly allocated 2- to 6-week periods on placebo, 1.25 mg/day ramipril, and 5 mg/day ramipril in a double-blind, cross-over study. During normoglycemia, the hemodynamic changes induced by ramipril were similar in both genotypes. During hyperglycemia, the changes induced by ramipril were accentuated in the II genotype group and attenuated dose dependently in the D allele group (treatment-genotype interaction P values for ERPF, 0.018; MAP, 0.018; and total renal resistances, 0.055). These results provide a basis to different renal responses to ACE inhibition according to ACE genotype in type 1 diabetes.
authors.affiliation: Department of Medicine, Centre Hospitalier Universitaire du Sart Tilman, Liege, Belgium.
authors.forename: Laurent
authors.initials: L
authors.lastname: Weekers
authors.forename: Béatrice
authors.initials: B
authors.lastname: Bouhanick
authors.forename: Samy
authors.initials: S
authors.lastname: Hadjadj
authors.forename: Yves
authors.initials: Y
authors.lastname: Gallois
authors.forename: Ronen
authors.initials: R
authors.lastname: Roussel
authors.forename: Franck
authors.initials: F
authors.lastname: Pean
authors.forename: Amos
authors.initials: A
authors.lastname: Ankotche
authors.forename: Gilles
authors.initials: G
authors.lastname: Chatellier
authors.forename: François
authors.initials: F
authors.lastname: Alhenc-Gelas
authors.forename: Pierre J
authors.initials: PJ
authors.lastname: Lefebvre
authors.forename: Michel
authors.initials: M
authors.lastname: Marre
mesh_terms: D000328:Adult; D000419:Albuminuria; D000450:Aldosterone / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D005260:Female; D017353:Gene Deletion; D005838:Genotype; D005919:Glomerular Filtration Rate; D006439:Hemodynamics; D006801:Humans; D006943:Hyperglycemia / Q000201:enzymology*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects*; D008297:Male; D016254:Mutagenesis, Insertional; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000235:genetics*; D011110:Polymorphism, Genetic; D017257:Ramipril / Q000627:therapeutic use; D012083:Renin / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000450:Aldosterone; D007703:Peptidyl-Dipeptidase A; D012083:Renin; D017257:Ramipril